Compositions and Methods of Treating Tumors

Anti-malignant tumor agent

Bispecific anti-VEGF/anti-ANG-2 antibodies

Surrogate binding proteins which bind DR4 and/or DR5

Treatment of ocular neovascularization using anti-VEGF proteins

Protein complex, bispecific antibody including the protein complex, and method of preparation thereof

Anti-Bv8 antibodies and uses thereof

Anti-Trop-2 antibody-drug conjugates and uses thereof

Anti-KDR antibodies and methods of use

Anti-HER3 antibodies and uses thereof

Vaccines against antigens involved in therapy resistance and methods of using same

Anti-glucosaminidase passive immunization for infections

Antibodies immunoreactive with heregulin-coupled HER3

Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5

IgE antibodies for the inhibition of tumor metastasis

Antibodies

CYTOTOXIC IMMUNOGLOBULIN

BINDING AGENTS TO INTRACELLULAR TARGET MOLECULES

Binding molecules specific for HER3 and uses thereof

Antibodies specific for trop-2 and their uses

Method of target membrane protein depletion

Multivalent fibronectin based scaffold domain proteins

Antibiotic preparation method and platform system based on same

Nucleic acids that encode interleukin-6 receptor binding polypeptides

Methods of treating autoimmune diseases by administering monoclonal antibodies against human IL-12

Binding molecules for BCMA and CD3

Methods and antibodies for treating cancer

Methods for blocking or reducing binding of interleukin-6 to interleukin-6 receptor

Monoclonal antibodies to Programmed Death 1 (PD-1)

Anti-PD-L1 antibodies and uses thereof

Biological materials related to c-Met

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

Antibodies against human CSF-1R and uses thereof

Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof

Methods for treating cancer using anti-PD-1 antibodies

AGR2 blocking antibody and use thereof

Antibodies that bind OV064 and methods of use therefor

Antibodies reactive with B7-H3 and uses thereof

Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Multivalent antibodies and uses therefor

Methods of inhibiting tumor growth by antagonizing IL-6 receptor

Treatment of hematologic malignancies with an anti-CXCR4 antibody

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

Antibodies to TIP-1

Biological materials and uses thereof

Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist

Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells

Compositions and methods for diagnosis and treatment of hepatic cancers

Endoglin antibodies

Immunopotentiative composition

Combination immunotherapy for the treatment of cancer

Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Method of treating cancer using anti-c-Met antibody and FGFR inhibitor combination therapy

Anti-ErbB3 antibodies and uses thereof

Pertuzumab variants and evaluation thereof

Anti-Axl antibodies and uses thereof

Combination therapy using anti-C-met antibody and anti-ang-2 antibody

Multispecific and multivalent binding proteins and uses thereof

ANTI-C-MET tandem Fc bispecific antibodies

Method of treating solid cancers using anti-c-Met antibody and sorafenib combination therapy

Anti-c-Met/anti-EGFR bispecific antibodies

Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume

Compositions including triciribine and trastuzumab and methods of use thereof

Antibody drug conjugates

Antagonistic DR3 ligands

Monoclonal antibodies to programmed death 1 (PD-1)

Biological materials related to c-Met

Hybrid constant regions

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

Macromolecular compositions that cross the blood-brain barrier and methods of use thereof

Notch agonists for the treatment of cancer

Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide

Anti-human IL-23 receptor antibody

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

Antibody drug conjugates

Combinations of kinase inhibitors for the treatment of cancer

Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

Anti-notch NRR antibodies and methods using same

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)

Antibodies to HGF and compositions containing

Methods of blocking cancer stem cell growth

Method for increasing M1 macrophages in a patient

Bispecific EGFR/c-Met antibodies

Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Bispecific T cell activating antigen binding molecules

Methods and monitoring of treatment with a Wnt pathway inhibitor

M-CSF specific monoclonal antibody and uses thereof

Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer

Antibodies to CD70

Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same

Antibodies against the ectodomain of ERBB3 and uses thereof

Monoclonal antibody against human non-small cell lung carcinoma and use thereof

Method for decreasing radioresistance and growth, metastasis and infiltration of cancer cells through regulating expression or activity of TM4SF4 in non-small cell lung cancer

Treatment of neurological conditions

Method of modulating the activity of functional immune molecules

Prolactin receptor binding proteins and uses thereof

Annexin A2 as immunological target

Anti-pseudomonas Psl binding molecules and uses thereof

Anti-Axl antibodies and uses thereof

Combination therapy of anti-HER3 antibodies

Humanized anti-HLA-DR antibodies

Humanization of rabbit antibodies using a universal antibody framework

Interleukin-6 receptor binding polypeptides

Monovalent binding proteins

Methods of modulating HVEM, BTLA and CD160 cis complex response or signaling activity with soluble light polypeptide sequences

C(epsilon)mX peptides for inducing immune responses to human mIgE on B lymphocytes

Method of inhibiting cancer in a mammal by administering an antibody to PTHrP

Humanized anti-CD4 antibody with immunosuppressive properties

Fusion protein for suppressing cancer cell growth and suppressing vasculogenesis, and anticancer composition comprising same

Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies

Anti-FOLR1 antibody

Anti c-Met antibodies

Siglec-15 antibodies in treating bone loss-related disease

Polypeptide that binds aberrant cells and induces apoptosis

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

DDR1-binding agents and methods of use thereof

Compositions and methods for antibodies targeting EPO

Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (VEGFR—2/KDR)

Anti-hDlk-1 antibody having an antitumor activity in vivo

Bispecific anti-EGFR/anti IGF-1R antibodies

Monoclonal antibodies against Glypican-3

Pharmaceutical composition for treatment and/or prophylaxis of cancer

Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4

Polynucleotides encoding anti-CD40 antibodies

Inhibitors of type 2 vascular endothelial growth factor receptors

Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins

Method for producing a multivalent fab fragment with collagen-like peptide

Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution

Antibody-like proteins for therapeutic and diagnostic use

Therapeutic CD47 antibodies

EGFR and C-Met fibronectin type III domain binding molecules

EGFR and c-Met fibronectin type III domain binding molecules

Polynucleotides encoding BSL2v2c2-Ig

Method for the treatment of inflammatory disorders

Compositions and methods for diagnosing and treating cancer

Polypeptides, antibody variable domains and antagonists

Antibodies to CD70

Human monoclonal antibodies to epidermal growth factor receptor (EGFR)

Neutralizing prolactin receptor antibody Mat3 and its therapeutic use

Bispecific EGFR/c-Met antibodies

Humanized L243 antibodies

Humanised anti-CD52 antibodies

Antibodies to TGF-beta

Antibodies for treatment of cancer

Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal antibody variable regions

Treatment and prevention of cancer with HMGB1 antagonists

Anti CEACAM1 antibodies and methods of using same

Photosensitizing antibody-fluorophore conjugates

Treatment of tumors using specific anti-L1 antibody

Antibodies to EphA3

Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A

Anti-CD40 antibodies and methods of use

Bispecific IgG antibodies as T cell engagers

Antigen binding proteins that bind ErbB3

Cross-linking polypeptide that induces apoptosis

Antibodies to insulin-like growth factor I receptor

Modulation of NKG2D for prolonging survival of a hematopoietic graft

Antibodies to interleukin-6

Methods for treating malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)

Cytotoxicity-inducing therapeutic agent

Anti-FcRH5 antibodies and immunoconjugates and methods of use

Human C-FMS antibodies

Modulators of Plexin B2 activity

Use of LRIG1 as a biomarker for identifying a subject for application of anti-c-Met antibodies

Use of Cbl as biomarker for identifying subject suitable for treatment with anti-c-Met antibody

Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same

Anti-IL13 antibodies and uses thereof

HERV-K antigens, antibodies, and methods

Anti-IL-6 antibodies, compositions, methods and uses

EGFR-binding molecules and immunoconjugates thereof

Anti-CD79B antibodies and immunoconjugates and methods of use

Camptothecin-binding moiety conjugates

Combination therapy for inducing immune response to disease

Therapeutic DLL4 binding proteins

Modulators and methods of use

Antigenic GM-CSF peptides and antibodies to GM-CSF

FGFR1 antibodies and treatment of cancer

Immunological compositions as cancer therapeutics

Recombinant antibodies to the vascular endothelial growth factor (VEGF) which are obtained by means of mutagenesis of variable regions

Compositions and methods for the diagnosis and treatment of tumor

Compositions and methods for the diagnosis and treatment of tumor

Anti-tissue factor antibodies and compositions

Molecules with antigen binding and polyvalent FC gamma receptor binding activity

Anti-CD100 antibodies and methods of using the same

Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis

Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody

High affinity antibodies that neutralize enterotoxin B

Antibodies against human angiopoietin 2

Antibodies against human angiopoietin 2

Anti-DCLK1 monoclonal antibodies and methods of production and use thereof

Method of treating hypertension disorder and a pharmaceutical agent

Anti-HER antibodies

Anti-CD19 antibodies and uses in B cell disorders

Method of treating pulmonary disease by administering an antibody to G-CSF

Methods for diagnosing and treating neuroendocrine cancer

Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair

Anti-CXCR4 antibodies and their use for the treatment of cancer

T-cell redirecting bispecific antibodies for treatment of disease

Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use

Human monoclonal antibodies specific for glypican-3 and use thereof

Therapeutic method and medicament for HTLV-1 associated myelopathy

Antigen binding formats for use in therapeutic treatments or diagnostic assays

Humanized single-chain antibody against beta 3 integrin for the treatment and prevention of metastasis

Human antibodies and antibody-drug conjugates against CD74

Non-antagonistic EGFR-binding molecules and immunoconjugates thereof

Antibody with specificity for GM-CSF (I)

Immunotherapy against ErbB-3 receptor

Fully human antibodies to BTLA

Antibody for 3′-isoLM1 and 3′,6′-iso-LD1 gangliosides

Antibodies to endoplasmin and their use

Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof

Biological inhibitors of ROR1 capable of inducing cell death

Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma

Anti-DR5 antibodies, polynucleotides and methods

B-cell reduction using CD37-specific and CD20-specific binding molecules

Stable and soluble antibodies inhibiting VEGF

Therapeutic peptides

Anti-human TROP-2 antibody having an antitumor activity in vivo

Anti-EGFR antibodies and uses thereof

Anti-VEGF-C antibodies and methods using same

Photosensitizing antibody-fluorophore conjugates

Antagonistic DR3 ligands

Binding members for interleukin-4 receptor alpha (IL-4Rα) - 173

Anti-TrkA antibodies, derivatives and uses thereof

Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody

Anti-LGR5 antibodies and immunoconjugates

Anti-ErbB3 antibodies

Antagonistic DR3 ligands

Anti-IL-1β antibodies

Antibody and methods for selective inhibition of T-cell responses

Anti-NGF antibodies and their use

Antibody molecules having specificity for human OX40

Antibodies for epidermal growth factor receptor 3 (HER3)

Antigen binding proteins that bind PD-L1

Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy

Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95

Anti-VEGF antibodies

Methods and compositions for inhibiting CD32B expressing cells

Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to NaPi2B transporter

Methods and compositions combining immunotherapy with monocyte activation

Antagonists of IL-17A, IL-17F, and IL-23P19

Antibodies that bind epidermal growth factor receptor (EGFR)

Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

CD89 activation in therapy

Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same

Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL

Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes

Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin

Antibodies against nerve growth factor (NGF) with enhanced in vivo stability

Anti-ephrin-B2 antibody and compositions comprising it

Anti-FGFR3 antibodies and methods using same

Anti-HER3 antibodies and compositions

Antibodies against ROR1 and uses thereof

B cell maturation antigen (BCMA) binding proteins

Anti-BAFF-anti-IL-17 bispecific antibodies

Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy

Humanized antibodies with anti-tumor activity

Compositions and methods for treating neoplasia

Method of PLSCR inhibition for cancer therapy

Stable Tregs and related materials and methods

Binding proteins specific for insulin-like growth factors and uses thereof

Anti-CD100 neutralizing antibodies and methods of using the same

Dendritic cell marker and uses thereof

Therapeutic antibodies against ROR-1 protein and methods for use of same

Antibodies against a proliferating inducing ligand (APRIL) and methods of use thereof

Neutralizing prolactin receptor antibodies and their therapeutic use

Anti-Notch1 antibodies

Anti-VEGF antibodies

Targeting intracellular target-binding determinants with intracellular antibodies

Moesin modulators and uses thereof

Compositions and methods for treatment of drug resistant multiple myeloma

Methods for treating a tumor using an antibody that specifically binds HMW-MAA

Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof

Method for making Heteromultimeric molecules

Nucleic acids encoding human monoclonal antibodies that bind CXCR4

Anti-ROR1 antibodies and methods of use for treatment of cancer

Compositions and methods for the treatment of immune related diseases

Human anti-CD27 antibodies, methods and uses

Notch1 binding agents and methods of use thereof

Antibody molecules having specificity for human OX40

Method for cancer detection

Anti-Axl antibodies and methods of use

Engineered polypeptide conjugates and methods for making thereof using transglutaminase

Methods of treating cancer by administering EMP2 antibodies

Protein complexes for antigen binding and methods of use

Anti-single-chain type IV collagen polypeptide antibody, pharmaceutical drug, diagnostic, preventive, or therapeutic drug for tumour containing the antibody

ErbB3 binding antibody

Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma

Single chain variable fragment anti-CD133 antibodies and uses thereof

Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile

Method of providing disease-specific binding molecules and targets

Anti-La antibodies and their use for immunotargeting

Anti-GD2 antibodies

Fab-glycosylated antibodies

Humanized anti-CDCP1 antibodies

DNA encoding an anti-system ASC amino acid transporter 2 (ASCT2) antibody

Antibody drug conjugates (ADC) that bind to 191P4D12 proteins

High affinity antibodies that neutralize enterotoxin B

Anti-CD19 antibody having ADCC function with improved glycosylation profile

Anti-human epidermal growth factor receptor antibody and uses thereof